Drug Profile

SHR 1802

Alternative Names: SHR-1802

Latest Information Update: 28 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Aug 2023 No recent reports of development identified for phase-I development in Cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral)
27 Jun 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease) (Parenteral)
27 Jun 2023 Phase-II clinical trials in Solid tumours (Combination therapy, In the elderly, Late-stage disease, In adults) in China (Parenteral) (Jiangsu HengRui Medicine pipeline, June 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com